olopatadine
Trade name: patanol
Approved
Dec 18, 1996
Olopatadine is an antihistamine (as well as anticholinergic and mast cell stabilizer) used to treat itching associated with allergic conjunctivitis (eye allergies). Olopatadine is a selective histamine H1 antagonist that binds to the histamine H1 receptor. This blocks the action of endogenous histamine, which subsequently leads to temporary relief of the negative symptoms brought on by histamine. Olopatadine is devoid of effects on alpha-adrenergic, dopamine and muscarinic type 1 and 2 receptors. Some known side effects include a headache (7% of occurrence), eye burning and/or stinging (5%), blurred vision, dry eyes, foreign body sensation, hyperemia, keratitis, eyelid edema, pruritus, asthenia, sore throat (pharyngitis), rhinitis, sinusitis, and taste perversion. — NCATS
Clinical trial activity
69 trials · 37 clinical orgs · 34 marketing orgs
Earliest trial started Sep 1, 2000 (NCT00609128)
Timeline
1990s
2000s
2010s
- Jan 28, 2010
Sandoz — Marketing Organization
- Jan 28, 2010
Novartis — Marketing Organization
- Jan 1, 2011
- Aug 27, 2014
Actavis — Marketing Organization
- Oct 8, 2014
Apotex — Marketing Organization
- Jan 30, 2015
Alcon — Marketing Organization
- Feb 2, 2015
Watson Pharmaceuticals — Marketing Organization
- Jul 13, 2015
Barr Laboratories — Marketing Organization
- Jul 13, 2015
Teva — Marketing Organization
- Dec 7, 2015
Somerset Pharmaceuticals — Marketing Organization
- Dec 7, 2015
USV — Marketing Organization
- Dec 7, 2015
Zambon — Marketing Organization
- Dec 18, 2015
Aurobindo Pharma — Marketing Organization
- Dec 18, 2015
Eugia Pharma — Marketing Organization
- Jan 10, 2017
Sciegen Pharmaceticals — Marketing Organization
- Jan 31, 2017
Perrigo — Marketing Organization
- Jan 31, 2017
Padagis Us — Marketing Organization
- Jun 28, 2017
Wockhardt — Marketing Organization
- Jun 28, 2017
Glenmark Pharmaceuticals — Marketing Organization
- Jul 26, 2017
Bausch Health Companies — Marketing Organization
- Jul 26, 2017
Cipla — Marketing Organization
- Jul 26, 2017
Bausch & Lomb — Marketing Organization
- Dec 5, 2017
Akorn, Inc. — Marketing Organization
- Mar 21, 2018
Mylan — Marketing Organization
- Mar 21, 2018
Rising Pharmaceuticals — Marketing Organization
- Dec 7, 2018
Alembic — Marketing Organization
- Aug 2, 2019
Gland Pharma Ltd — Marketing Organization
- Aug 2, 2019
Fosun — Marketing Organization
- Sep 26, 2019
FDC — Marketing Organization
2020s
- Jan 28, 2020
Amneal Pharmaceuticals — Marketing Organization
- Feb 19, 2020
AbbVie — Marketing Organization
- Feb 19, 2020
Lachman Consultants — Marketing Organization
- Jun 16, 2020
Micro Labs Ltd India — Marketing Organization
- Aug 19, 2020
Hikma — Marketing Organization
- Jan 13, 2022
Glenmark Pharmaceuticals — NDA Secondary Org
Indications
Mechanism of action
- Histamine H1 receptorANTAGONIST
HRH1 antagonist
Combination products
ryaltris
with mometasone
Approval history
- approvedDec 18, 1996
Chemistry & pharmacology
SMILES
CN(C)CC/C=C1/c2ccccc2COc2ccc(CC(=O)O)cc21- Mol. weight
- 337.42 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Topical
- Availability
- Over the Counter
Oral
No
Parenteral
No
Topical
Yes
Sources
- ChEMBLCHEMBL1189432 ↗
- WikipediaOlopatadine ↗
- NCATSD27V6190PM ↗
- ChEMBLCHEMBL1719 ↗
Also known as
- ac 170
- ac 170
- ac-170
- ac-170
- al-4943a
- al-4943a
- alo-4943a
- alo-4943a
- kw-4679
- kw-4679
- olopatadin
- olopatadin
- olopatadina
- olopatadina
- olopatadine
- olopatadine
- olopatadine
- olopatadine
- olopatadine
- olopatadine
- olopatadine
- olopatadine
- olopatadine
- olopatadine
- olopatadine hcl
- olopatadine hcl
- olopatadine hcl
- olopatadine hydrochloride
- olopatadine hydrochloride
- olopatadine hydrochloride
- olopatadine hydrochloride
- olopatadine hydrochloride
- olopatadinum
- olopatadinum
- opatanol
- opatanol
- opatanol
- opatanol
- pataday
- pataday
- pataday
- patanase
- patanase
- patanol
- patanol
- patanol
- patanol
- t1210
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06126952 | Phase 2 | Oct 30, 2023 | Cliantha Research Limited, Meda Pharmaceuticals |
| NCT05314621 | Phase 4 | Dec 31, 2021 | Andover Research Eye Institute |
| NCT05265910 | Phase 4 | Dec 14, 2021 | Andover Research Eye Institute |
| NCT04776096 | Phase 4 | Mar 10, 2021 | Laboratorios Poen |
| NCT04708821 | Phase 4 | Feb 15, 2021 | Florida Clinical Research Center, LLC, Ocular Therapeutix, Inc. |
| NCT03463031 | Phase 3 | Mar 16, 2018 | Glenmark Pharmaceuticals |
| NCT03320434 | Phase 2 | Oct 13, 2017 | ORA, Inc. |
| NCT02870205 | Phase 3 | Aug 1, 2016 | Glenmark Pharmaceuticals |
| NCT02709538 | Phase 3 | Apr 1, 2016 | Glenmark Pharmaceuticals |
| NCT02756624 | Phase 3 | Apr 1, 2016 | NicOx, ORA, Inc. |
| NCT02631551 | Phase 3 | Mar 1, 2016 | Glenmark Pharmaceuticals |
| NCT02478398 | Phase 3 | Jul 20, 2015 | Merck |
| NCT02322216 | Phase 3 | Dec 1, 2014 | Alcon |
| NCT02318303 | Phase 2 | Dec 1, 2014 | Glenmark Pharmaceuticals |
| NCT01657240 | Phase 3 | Nov 1, 2014 | Laboratorios Sophia S.A de C.V. |
| NCT02161146 | Phase 3 | Jun 1, 2014 | Allergan |
| NCT02173249 | Phase 1 | Jun 1, 2014 | Aciex Therapeutics, Inc. |
| NCT02132169 | Phase 3 | May 1, 2014 | Aciex Therapeutics, Inc. |
| NCT03444506 | Phase 2 | Jan 27, 2014 | Glenmark Pharmaceuticals |
| NCT02251613 | Phase 4 | Dec 1, 2013 | Alcon |
Organizations
Research & Development (37)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Alcon | For profit | 26 | 26 | 4 | 2006 |
| Aciex Therapeutics, Inc. | For profit | 7 | 7 | 2 | 2011 |
| Glenmark Pharmaceuticals | For profit | 6 | 6 | 2 | 2014 |
| ORA, Inc. | For profit | 5 | 2 | 3 | 2008 |
| Allergan | For profit | 4 | 4 | 2 | 2010 |
| Merck | For profit | 4 | 3 | 2 | 2007 |
| ALK-Abello, S.A. | For profit | 2 | 2 | 1 | 2007 |
| Andover Research Eye Institute | Academic/Hospital | 2 | 2 | 1 | 2021 |
| Santen Inc. | For profit | 2 | 2 | 1 | 2011 |
| Bausch & Lomb | For profit | 1 | 1 | 1 | 2010 |
| Central Texas Allergy and Asthma | Academic/Hospital | 1 | 0 | 1 | 2008 |
| Cliantha Research Limited | For profit | 1 | 0 | 1 | 2023 |
| Florida Clinical Research Center, LLC | For profit | 1 | 1 | 1 | 2021 |
| GlaxoSmithKline | For profit | 1 | 0 | 1 | 2009 |
| Gulf Coast Research Associates, Inc | For profit | 1 | 0 | 1 | 2008 |
| Harvard University | Academic/Hospital | 1 | 1 | 1 | 2008 |
| Hom, Milton M., OD, FAAO | Academic/Hospital | 1 | 1 | 1 | 2007 |
| Laboratoires Thea | For profit | 1 | 1 | 1 | 2011 |
| Laboratorios Poen | For profit | 1 | 1 | 1 | 2021 |
| Laboratorios Sophia S.A de C.V. | For profit | 1 | 1 | 1 | 2014 |
Marketing (47)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| AbbVie | For profit | MKTG | Feb 19, 2020 |
| Actavis | For profit | MKTG | Aug 27, 2014 |
| Akorn, Inc. | For profit | MKTG | Dec 5, 2017 |
| Akorn, Inc. | For profit | SYN | Jan 10, 2017 |
| Alcon | For profit | MKTG | Jan 30, 2015 |
| Alembic | For profit | MKTG | Dec 7, 2018 |
| Alembic | For profit | SYN | Dec 7, 2018 |
| Amneal Pharmaceuticals | For profit | SYN | Jan 28, 2020 |
| Amneal Pharmaceuticals | For profit | MKTG | Jan 28, 2020 |
| Apotex | For profit | SYN | Dec 7, 2015 |
| Apotex | For profit | MKTG | Oct 8, 2014 |
| Aurobindo Pharma | For profit | MKTG | Dec 18, 2015 |
| Barr Laboratories | For profit | MKTG | Jul 13, 2015 |
| Bausch & Lomb | For profit | MKTG | Jul 26, 2017 |
| Bausch Health Companies | For profit | MKTG | Jul 26, 2017 |
| Cipla | For profit | MKTG | Jul 26, 2017 |
| Eugia Pharma | For profit | MKTG | Dec 18, 2015 |
| FDC | For profit | MKTG | Sep 26, 2019 |
| Fosun | For profit | MKTG | Aug 2, 2019 |
| Gland Pharma Ltd | For profit | MKTG | Aug 2, 2019 |
| Gland Pharma Ltd | For profit | SYN | Aug 2, 2019 |
| Glenmark Pharmaceuticals | For profit | MKTG | Jun 28, 2017 |
| Glenmark Pharmaceuticals | For profit | NDA2 | Jan 13, 2022 |
| Glenmark Pharmaceuticals | For profit | SYN | Jan 13, 2022 |
| Hikma | For profit | MKTG | Aug 19, 2020 |
| Lachman Consultants | For profit | MKTG | Feb 19, 2020 |
| Micro Labs Ltd India | For profit | MKTG | Jun 16, 2020 |
| Mylan | For profit | SYN | Mar 21, 2018 |
| Mylan | For profit | MKTG | Mar 21, 2018 |
| Nestle | For profit | NDA2 | Dec 18, 1996 |
| Novartis | For profit | NDA2 | Dec 18, 1996 |
| Novartis | For profit | NDA | Dec 18, 1996 |
| Novartis | For profit | MKTG | Jan 28, 2010 |
| Padagis Us | For profit | MKTG | Jan 31, 2017 |
| Perrigo | For profit | MKTG | Jan 31, 2017 |
| Rising Pharmaceuticals | For profit | MKTG | Mar 21, 2018 |
| Sandoz | For profit | MKTG | Jan 28, 2010 |
| Sciegen Pharmaceticals | For profit | MKTG | Jan 10, 2017 |
| Somerset Pharmaceuticals | For profit | MKTG | Dec 7, 2015 |
| Somerset Pharmaceuticals | For profit | SYN | Dec 18, 2024 |
| Teva | For profit | MKTG | Jul 13, 2015 |
| USV | For profit | SYN | Dec 7, 2015 |
| USV | For profit | MKTG | Dec 7, 2015 |
| Watson Pharmaceuticals | For profit | MKTG | Feb 2, 2015 |
| Watson Pharmaceuticals | For profit | SYN | Aug 27, 2014 |
| Wockhardt | For profit | MKTG | Jun 28, 2017 |
| Zambon | For profit | MKTG | Dec 7, 2015 |